FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004985536> ?p ?o ?g. }

• W2004985536 endingPage "2106" @default.
• W2004985536 startingPage "2101" @default.
• W2004985536 abstract "The purpose of this study was to determine the efficacy of and tolerance to antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndrome (MDS). Therapy consisted of ATG 40 mg/kg/day daily intravenously (i.v.) for 4 days; cyclosporine daily orally for 6 months with levels titrated between 200 and 400 mg/dl; and methylprednisone 1 mg/kg i.v. daily before each dose of ATG. Of 32 patients treated, 31 patients were evaluable. The median age was 59 years (range, 28–79 years). A total of 18 patients had refractory anemia (RA) or RA with ringed sideroblasts (RARS), 10 patients had RA with excess blasts (RAEB), two patients had RAEB in transformation, and one patient had chronic myelomonocytic leukemia. ATG, cyclosporine, and methylprednisone induced complete (N=4) or partial (N=1) remission in five patients (16% of total; RA, two patients; RARS, two patients; and RAEB, one patient). Durable complete remissions were observed in three of 18 patients (17%) with RA (N=1) or RARS (N=2) (12, 41+, and 60+ months). The most common adverse events were fever and allergic reactions. Hepatic and renal dysfunction, albeit consistently reversible, occurred in 19 and 13% of the patients, respectively. In conclusion, an ATG-based regimen can produce durable complete remissions in a subset of patients with MDS." @default.
• W2004985536 created "2016-06-24" @default.
• W2004985536 creator A5044840107 @default.
• W2004985536 creator A5053481267 @default.
• W2004985536 creator A5057920623 @default.
• W2004985536 creator A5061285204 @default.
• W2004985536 creator A5084455291 @default.
• W2004985536 creator A5090435894 @default.
• W2004985536 creator A5091177812 @default.
• W2004985536 date "2003-08-21" @default.
• W2004985536 modified "2023-10-16" @default.
• W2004985536 title "Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes" @default.
• W2004985536 cites W105676805 @default.
• W2004985536 cites W121813311 @default.
• W2004985536 cites W1494325974 @default.
• W2004985536 cites W1512073250 @default.
• W2004985536 cites W1519963426 @default.
• W2004985536 cites W15200801 @default.
• W2004985536 cites W1541533982 @default.
• W2004985536 cites W1565660186 @default.
• W2004985536 cites W1580063028 @default.
• W2004985536 cites W1592664872 @default.
• W2004985536 cites W1766869021 @default.
• W2004985536 cites W1851142847 @default.
• W2004985536 cites W1923634318 @default.
• W2004985536 cites W1967528790 @default.
• W2004985536 cites W1973034088 @default.
• W2004985536 cites W1974496004 @default.
• W2004985536 cites W1980149121 @default.
• W2004985536 cites W1981978962 @default.
• W2004985536 cites W1995314148 @default.
• W2004985536 cites W1995837413 @default.
• W2004985536 cites W2000566171 @default.
• W2004985536 cites W2004089260 @default.
• W2004985536 cites W2005014251 @default.
• W2004985536 cites W2012709673 @default.
• W2004985536 cites W2015881261 @default.
• W2004985536 cites W2017868278 @default.
• W2004985536 cites W2018139126 @default.
• W2004985536 cites W2025487178 @default.
• W2004985536 cites W2026660305 @default.
• W2004985536 cites W2027178014 @default.
• W2004985536 cites W2033292292 @default.
• W2004985536 cites W2038584260 @default.
• W2004985536 cites W2053333573 @default.
• W2004985536 cites W2054190982 @default.
• W2004985536 cites W2069757957 @default.
• W2004985536 cites W2072503775 @default.
• W2004985536 cites W2080015990 @default.
• W2004985536 cites W2084867499 @default.
• W2004985536 cites W2094693991 @default.
• W2004985536 cites W2106584820 @default.
• W2004985536 cites W2110949925 @default.
• W2004985536 cites W2118605967 @default.
• W2004985536 cites W2129975746 @default.
• W2004985536 cites W2148281444 @default.
• W2004985536 cites W2313306229 @default.
• W2004985536 cites W2341016096 @default.
• W2004985536 cites W2410421515 @default.
• W2004985536 cites W254128381 @default.
• W2004985536 cites W306283711 @default.
• W2004985536 cites W4247972768 @default.
• W2004985536 cites W4253670191 @default.
• W2004985536 cites W4253916874 @default.
• W2004985536 doi "https://doi.org/10.1038/sj.leu.2403124" @default.
• W2004985536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12931212" @default.
• W2004985536 hasPublicationYear "2003" @default.
• W2004985536 type Work @default.
• W2004985536 sameAs 2004985536 @default.
• W2004985536 citedByCount "76" @default.
• W2004985536 countsByYear W20049855362012 @default.
• W2004985536 countsByYear W20049855362013 @default.
• W2004985536 countsByYear W20049855362014 @default.
• W2004985536 countsByYear W20049855362015 @default.
• W2004985536 countsByYear W20049855362016 @default.
• W2004985536 countsByYear W20049855362017 @default.
• W2004985536 countsByYear W20049855362018 @default.
• W2004985536 countsByYear W20049855362019 @default.
• W2004985536 countsByYear W20049855362021 @default.
• W2004985536 crossrefType "journal-article" @default.
• W2004985536 hasAuthorship W2004985536A5044840107 @default.
• W2004985536 hasAuthorship W2004985536A5053481267 @default.
• W2004985536 hasAuthorship W2004985536A5057920623 @default.
• W2004985536 hasAuthorship W2004985536A5061285204 @default.
• W2004985536 hasAuthorship W2004985536A5084455291 @default.
• W2004985536 hasAuthorship W2004985536A5090435894 @default.
• W2004985536 hasAuthorship W2004985536A5091177812 @default.
• W2004985536 hasBestOaLocation W20049855361 @default.
• W2004985536 hasConcept C126322002 @default.
• W2004985536 hasConcept C141071460 @default.
• W2004985536 hasConcept C142424586 @default.
• W2004985536 hasConcept C2777928532 @default.
• W2004985536 hasConcept C2778248108 @default.
• W2004985536 hasConcept C2780007613 @default.
• W2004985536 hasConcept C2780817109 @default.
• W2004985536 hasConcept C2781413609 @default.
• W2004985536 hasConcept C71924100 @default.
• W2004985536 hasConcept C86803240 @default.

• next